ATTN: As of June 9, our Harbour View office in Suffolk has relocated to 3910 Bridge Road, Ste. 400.  

2025 UPDATES: Please bring all new insurance cards to your next appointment and verify your address and phone number when you check in at the front desk. 

Clinical Research & Trials

USO 23335

A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

 

Disease Types: Melanoma Research

Eligibility Requirements:

• Histologically confirmed unresectable stage III and stage IV
(metastatic) melanoma
• Uveal, acral or mucosal melanoma are not eligible
• No prior systemic therapy for unresectable or metastatic
melanoma
• Pt with adjuvant/neoadjuvant therapy without PD during treatment
are eligible if disease-free and treatment-free for over 6 months
• No prior immune checkpoint inhibitor therapy other than anti-PD1/PD-L1
• Measurable disease per RECIST version 1.1
• Previously irradiated lesions can be used as target lesions only if
demonstrated to progress and no other target lesion is available
• Cutaneous lesions are considered non-target lesions
• Patients must have known BRAF V600 status

For more information on this trial CLICK HERE .

Available at: